Giiant Pharma announced today that it added $1.25 million to its seed financing round to ensure reaching clinical proof-of-concept.
Montreal-based Giiant’s $750,000 in funding from AQC Capital, plus $500,000 from CQDM, adds to the seed round closed last month to bring the company’s total funding to nearly $15 million.
Get the full story at our sister site, Drug Delivery Business News.